Evicenter
P&T meetings

Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted December 2025
Last updated
62 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Nonadvanced systemic mastocytosis

2 evidence topics · 1 source

Epidemiology in Denmark: study classification

“all patients with non-advanced SM were characterized as ISM.” (opens the source at this quote in a new tab)

Epidemiology in Denmark: ISM prevalence as of January 1, 2022

“The prevalences of MIS and ISM were 13.94 per 100,000 persons (95% CI: 12.89–15.04) and 9.36 per 100,000 (95% CI: 8.51–10.28), respectively” (opens the source at this quote in a new tab)